

APPLICANT(S): Shukla, et al.  
SERIAL NO.: 10/069,280  
FILED: July 24, 2002  
Page 2

### AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A pharmaceutical preparation for inhibiting herpes simplex virus type-1 (HSV-1) infection in a mammal comprising a substantially pure ~~heparin~~ heparan sulfate polysaccharide preparation enriched by at least 5 % for 3-O-sulfated glucosamine residues, wherein said substantially pure ~~heparin~~ heparan sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues is obtained by the process comprising the step of contacting a ~~heparin~~ heparan sulfate polysaccharide with a 3-OST-3 enzyme and a sulfate donor so as to produce a substantially pure ~~heparin~~ heparan sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues.
2. (Previously Amended) The pharmaceutical preparation of claim 1, wherein said polysaccharide preparation is enriched for GlcN3S6S.
3. Cancelled.
4. Cancelled.
5. Cancelled.
6. Cancelled.
7. Cancelled.
8. Cancelled.
9. Cancelled.
10. Cancelled.

APPLICANT(S): Shukla, et al.  
SERIAL NO.: 10/069,280  
FILED: July 24, 2002  
Page 3

11. (Currently Amended) The pharmaceutical preparation of claim 1, wherein said 3-OST-3 enzyme is selected from the group consist[[e]]ing of 3-OST-3A and 3-OST-3B.
12. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the disaccharide sequence -IdoA2S-GlcN3S6S.
13. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the trisaccharide sequence GlcNS-IdoA2S-GlcNH<sub>2</sub>3S6S.
14. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the tetrasaccharide sequence UA2S-GlcNS-IdoA2S-GlcNH<sub>2</sub>3S6S.
15. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the pentasaccharide sequence GlcNS6S-UA2S-GlcNS-IdoA2S-GlcNH<sub>2</sub>3S6S.
16. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the hexasaccharide sequence UA-GlcNS6S-UA2S-GlcNS-IdoA2S-GlcNH<sub>2</sub>3S6S.
17. Cancelled.
18. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the heptasaccharide sequence GlcNAc-UA-GlcNS6S-UA2S-GlcNS-IdoA2S-GlcNH<sub>2</sub>3S6S.
19. (Currently Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the octasaccharide sequence UA-GlcNAc-UA-GlcNS6S-UA2S-GlcNS-IdoA2S-GlcNH<sub>2</sub>3S6S.
20. (Currently Amended) The pharmaceutical preparation of claim 1, wherein said pharmaceutical preparation comprises pharmaceutically acceptable carriers selected from the group consisting of lotions, creams, jellies,

APPLICANT(S): Shukla, et al.  
SERIAL NO.: 10/069,280  
FILED: July 24, 2002  
Page 4

liniments, ointments, salves, oils, foams, gels, washes, suppositories, slow-releasing polymers, and coatings.

21. (Previously Amended) The pharmaceutical preparation of claim 1, wherein said pharmaceutical preparation further comprises at least one skin penetrating enhancer.
22. (Previously Amended) The pharmaceutical preparation of claim 21, wherein said skin penetrating enhancer is selected from the group consisting of dimethylsulfoxide (DMSO), propylene glycol, isopropanol, ethanol, oleic acid, and N-methylpyrrolidone.
23. (Currently Amended) A method of inhibiting herpes simplex virus type- I (HSV- 1) viral infection in mammal comprising administering to a mammal at risk of HSV- I infection a therapeutically effective amount of a pharmaceutical composition comprising a substantially pure ~~heparin~~ heparan sulfate polysaccharide preparation enriched by at least 5 % for 3-O-sulfated glucosamine residues, wherein said substantially pure ~~heparin~~ heparan sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues is obtained by the process comprising the step of contacting a ~~heparin~~ heparan sulfate polysaccharide with a 3-OST-3 enzyme and a sulfate donor.
24. (Currently Amended) A method of inhibiting herpes simplex virus type- I (HSV- 1) viral infection in mammal comprising administering to a mammal diagnosed with HSV- I infection a therapeutically effective amount of a pharmaceutical composition comprising a substantially pure ~~heparin~~ heparan sulfate polysaccharide preparation enriched by at least 5 % for 3-O-sulfated glucosamine residues, wherein said substantially pure ~~heparin~~ heparan sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues is obtained by the process comprising the step of contacting a ~~heparin~~ heparan sulfate polysaccharide with a 3-OST-3 enzyme and a sulfate donor.

APPLICANT(S): Shukla, et al.  
SERIAL NO.: 10/069,280  
FILED: July 24, 2002  
Page 5

25. (Previously Amended) The method of claim 23 or 24, wherein said polysaccharide preparation is enriched for structures capable of specific binding with HSV- 1 gD viral glycoprotein.
26. (Previously Amended) The method of claim 23 or 24, wherein said 3-OST-3 enzyme is selected from the group consisting of 3-OST-3A and 3-OST-3B.
27. (Previously Amended) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the disaccharide sequence -IdoA2S-GlcN3S6S.
28. (Previously Amended) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the trisaccharide sequence GlcNS-IdoA2S-GlcNH23S6S.
29. (Currently Amended) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the ~~tetrasaccharide~~ trisaccharide sequence UA2S-GlcNS-IdoA2S.
30. (Previously Amended) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the pentasaccharide sequence GlcNS6S-UA2S-GlcNS-IdoA2S-GlcNH23S6S.
31. (Previously Amended) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the hexasaccharide sequence UA-GlcNS6S-UA2S-GlcNS-IdoA2S-GlcNH23S6S.
32. (Previously Amended) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the hexasaccharide sequence UA-GlcNS6S-UA2S-GlcNS-IdoA2S-GlcNH23S6S.
33. (Previously Amended) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the heptasaccharide sequence GlcNAc-UA-GlcNS6S-UA2S-GlcNS-IdoA2S-GlcNH23S6S.

APPLICANT(S): Shukla, et al.  
SERIAL NO.: 10/069,280  
FILED: July 24, 2002  
Page 6

34. (Previously Amended) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the octasaccharide sequence UA-GlcNAc-UA-GlcNS6S-UA2S-GlcNS-IdoA2SGlcNH23S6S.
35. (Previously Amended) The method of claim 23 or 24, wherein said pharmaceutical preparation comprises pharmaceutically acceptable carrier selected from the group consisting of lotions, creams, jellies, liniments, ointments, salves, oils, foams, gels, washes, suppositories, slow-releasing polymers, and coatings.
36. (Previously Amended) The method of claim 23 or 24, wherein said wherein said pharmaceutical preparation further comprises at least one skin penetrating enhancer.
37. (Previously Amended) The method of claim 23 or 24, wherein said skin penetrating enhancer is selected from the group consisting of dimethylsulfoxide (DMSO), propylene glycol, isopropanol, ethanol, oleic acid, and N-methylpyrrolidone.